{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:46:38Z","timestamp":1782351998115,"version":"3.54.5"},"reference-count":100,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory diseases deeply rooted in age-related immunosenescence and inflammaging. Conventional long-term glucocorticoid (GC) therapy poses significant metabolic and infectious risks for older adults, necessitating safer alternatives. This review critically evaluates the pathophysiological rationale and clinical efficacy of small-molecule drugs, including Janus kinase inhibitors (JAKi) and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), as steroid-sparing treatments for PMR and GCA. By selectively inhibiting intracellular networks like the JAK-STAT pathway and nucleotide biosynthesis, these agents aim to attenuate maladaptive inflammation. Clinical evidence highlights that JAK inhibitors, particularly upadacitinib for GCA and tofacitinib or baricitinib for PMR, demonstrate the potential to induce remission and significantly reduce the required GC burden in a subset of patients. Although methotrexate remains the primary csDMARD, its modest overall efficacy suggests it should be reserved for patients with definitive contraindications or restricted access to JAK inhibitors. Furthermore, novel therapies like clofutriben demonstrate potential in reversing GC-induced morbidities without compromising disease control. Ultimately, integrating targeted small-molecule immunomodulators establishes a crucial therapeutic paradigm that attempts to maximize clinical remission while safeguarding the physiological integrity of geriatric patients against severe GC toxicities.<\/jats:p>","DOI":"10.3390\/molecules31132218","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:03:56Z","timestamp":1782349436000},"page":"2218","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small-Molecule Strategies for Polymyalgia Rheumatica and Giant Cell Arteritis in Older Adults"],"prefix":"10.3390","volume":"31","author":[{"given":"Jan","family":"Kurdybacha","sequence":"first","affiliation":[{"name":"Students\u2019 Scientific Society, Department of Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksii","family":"Kravets","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Society, Department of Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8967-8505","authenticated-orcid":false,"given":"Natalia","family":"Lekston","sequence":"additional","affiliation":[{"name":"Students\u2019 Scientific Society, Department of Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Kotyla","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Medical Faculty in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Gumkowska-Sroka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical Faculty in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-6527","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Kotyla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical Faculty in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/09513590.2013.852531","article-title":"The Immune System and Aging: A Review","volume":"30","author":"Soveral","year":"2014","journal-title":"Gynecol. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12016-021-08899-6","article-title":"Immunology of Aging: The Birth of Inflammaging","volume":"64","author":"Fulop","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Schmeer, C., Kretz, A., Wengerodt, D., Stojiljkovic, M., and Witte, O.W. (2019). Dissecting Aging and Senescence\u2014Current Concepts and Open Lessons. Cells, 8.","DOI":"10.3390\/cells8111446"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1189\/jlb.3RI0716-335R","article-title":"Human T Cell Immunosenescence and Inflammation in Aging","volume":"102","author":"Bektas","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: Molecular Mechanisms and Diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"157\u2013176, ix\u2013x","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection Risk and Safety of Corticosteroid Use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E6301","DOI":"10.1073\/pnas.1515386112","article-title":"JAK Inhibition Alleviates the Cellular Senescence-Associated Secretory Phenotype and Frailty in Old Age","volume":"112","author":"Xu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Paroli, M., Caccavale, R., and Accapezzato, D. (2024). Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice. Cells, 13.","DOI":"10.3390\/cells13030267"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e233496","DOI":"10.1136\/bcr-2019-233496","article-title":"Immune Checkpoint Inhibitor Induced Large Vessel Vasculitis","volume":"13","author":"Henderson","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-Cell Responses in Giant Cell Arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.autrev.2017.05.004","article-title":"New Insights into the Pathogenesis of Giant Cell Arteritis","volume":"16","author":"Ciccia","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41433-019-0608-7","article-title":"A New Era for Giant Cell Arteritis","volume":"34","author":"Lyons","year":"2020","journal-title":"Eye"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Esen, I., Jiemy, W.F., Van Sleen, Y., Van Der Geest, K.S.M., Sandovici, M., Heeringa, P., Boots, A.M.H., and Brouwer, E. (2021). Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Dis-ease Monitoring and Treatment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214958"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/annrheumdis-2016-210792","article-title":"Endothelin-1 Promotes Vascular Smooth Muscle Cell Migration across the Artery Wall: A Mechanism Contributing to Vascular Remodelling and Intimal Hyperplasia in Giant-Cell Arteritis","volume":"76","author":"Lozano","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/ard.2007.070805","article-title":"Imatinib Mesylate Inhibits in Vitro and Ex Vivo Biological Responses Related to Vascular Occlusion in Giant Cell Arteritis","volume":"67","author":"Lozano","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6","article-title":"Platelet-Derived Growth Factor, Intimal Hyperplasia, and Ischemic Complications in Giant Cell Arteritis","volume":"41","author":"Kaiser","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4081\/reumatismo.2018.1048","article-title":"Pathogenesis of Polymyalgia Rheumatica","volume":"70","author":"Guggino","year":"2018","journal-title":"Reumatismo"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/art.1780390719","article-title":"Leukocyte Infiltration in Synovial Tissue from the Shoulder of Patients with Polymyalgia Rheumatica","volume":"39","author":"Meliconi","year":"1996","journal-title":"Arthritis Rheum. Off. J. Am. Coll. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/ard.2010.140194","article-title":"Expression and Function of Toll-like Receptors in Peripheral Blood Mononuclear Cells of Patients with Polymyalgia Rheumatica and Giant Cell Arteritis","volume":"70","author":"Mata","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/1529-0131(200011)43:11<2472::AID-ANR14>3.0.CO;2-B","article-title":"Vascular Endothelial Growth Factor Production in Polymyalgia Rheumatica","volume":"43","author":"Meliconi","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","article-title":"NKG2D Stimulated T-Cell Autoreactivity in Giant Cell Arteritis and Polymyalgia Rheumatica","volume":"72","author":"Dejaco","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 Lymphocytes Expressing CD161 Are Implicated in Giant Cell Arteritis and Polymyalgia Rheumati-ca Pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","article-title":"Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Poly-myalgia Rheumatica","volume":"66","author":"Abdulahad","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1187584","DOI":"10.3389\/fimmu.2023.1187584","article-title":"Clinical Experience and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis: A Retrospective Case Series from Sweden","volume":"14","author":"Eriksson","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ard.2025.09.005","article-title":"Understanding the Immunopatho-physiology of Polymyalgia Rheumatica: Implications for Treatment","volume":"85","author":"Choy","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard-2022-223562","article-title":"Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica: A Phase 2 Study","volume":"82","author":"Zhang","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5114\/reum.2020.101400","article-title":"Conventional Disease-Modifying Agents in Rheumatoid Arthritis\u2014A Review of Their Current Use and Role in Treatment Algorithms","volume":"58","author":"Padjen","year":"2020","journal-title":"Reumatologia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: Mode of Action in the Treatment of Rheumatoid Arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthet-ic and Biological Disease-Modifying Antirheumatic Drugs: 2022 Update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/13696998.2023.2299176","article-title":"Cost-Effectiveness Analysis of Upadacitinib as a Treatment Option for Patients with Rheumatoid Arthritis in the Kingdom of Saudi Arabia","volume":"27","author":"Sharma","year":"2024","journal-title":"J. Med. Econ."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The Regulation of JAKs in Cytokine Signaling and Its Breakdown in Disease","volume":"118","author":"Virtanen","year":"2019","journal-title":"Cytokine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25760","DOI":"10.1074\/jbc.M500822200","article-title":"The Jak1 SH2 Domain Does Not Fulfill a Classical SH2 Function in Jak\/STAT Signaling but Plays a Structural Role for Receptor Interaction and up-Regulation of Receptor Surface Expression","volume":"280","author":"Radtke","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1128\/MCB.20.10.3387-3395.2000","article-title":"Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain","volume":"20","author":"Saharinen","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bcp.2005.12.017","article-title":"JAK\/STAT Signal Transduction: Regulators and Implication in Hematological Malignancies","volume":"71","author":"Valentino","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: Transcriptional Control and Biological Impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102750","DOI":"10.1016\/j.autrev.2021.102750","article-title":"Working and Safety Profiles of JAK\/STAT Signaling Inhibitors. Are These Small Molecules Also Smart?","volume":"20","author":"Favoino","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK Inhibitors for the Treatment of Autoimmune and Inflammatory Diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib Is an Allosteric TYK2 Protein Kinase Inhibitor FDA-Approved for the Treatment of Psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10067-021-05973-4","article-title":"A Systematic Review of Clinical and Preclinical Evidences for Janus Kinase Inhibitors in Large Vessel Vasculitis","volume":"41","author":"Rathore","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK Selectivity and the Implications for Clinical Inhibition of Pharmacodynamic Cytokine Signalling by Filgotinib, Upadacitinib, Tofacitinib and Baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","first-page":"454","article-title":"A Platelet\u2019s Guide to Synovitis","volume":"21","author":"Cafaro","year":"2019","journal-title":"Isr. Med. Assoc. J. IMAJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102508","DOI":"10.1016\/j.autrev.2020.102508","article-title":"Precision Health: A Pragmatic Approach to Understanding and Addressing Key Factors in Autoimmune Diseases","volume":"19","author":"Conrad","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert Consensus Statement on the Treatment of Immune-Mediated Inflammatory Diseases with Janus Kinase Inhibitors: 2024 Update","volume":"84","author":"Nash","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of Action for Leflunomide in Rheumatoid Arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(96)00303-6","article-title":"Two Activities of the Immunosuppressive Metabolite of Leflunomide, A77 1726. Inhibition of Pyrimidine Nucleotide Synthesis and Protein Tyrosine Phosphorylation","volume":"52","author":"Xu","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4049\/jimmunol.159.1.22","article-title":"The Immunosuppressive Metabolite of Leflunomide, A77 1726, Affects Murine T Cells through Two Biochemical Mechanisms","volume":"159","author":"Elder","year":"1997","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of Action of Methotrexate in Rheumatoid Arthritis, and the Search for Biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The Antiinflammatory Mechanism of Methotrexate. Increased Adenosine Release at Inflamed Sites Diminishes Leukocyte Accumulation in an in Vivo Model of Inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 Receptors Are Required for Inhibition of Inflammation by Methotrexate and Its Analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive Properties of Methotrexate: Apoptosis and Clonal Deletion of Activated Peripheral T Cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.34342","article-title":"Methotrexate Increases Expression of Cell Cycle Checkpoint Genes via JNK Activation","volume":"64","author":"Spurlock","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate Mofetil and Its Mechanisms of Action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.4049\/jimmunol.169.5.2747","article-title":"Mycophenolic Acid Inhibits IL-2-Dependent T Cell Proliferation, but Not IL-2-Dependent Survival and Sensitization to Apoptosis","volume":"169","author":"Flacher","year":"2002","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/01.TP.0000127592.13707.B6","article-title":"Mycophenolate Mofetil Prevents Transplant Arteriosclerosis by Direct Inhibition of Vascular Smooth Muscle Cell Proliferation","volume":"77","author":"Shimizu","year":"2004","journal-title":"Transplantation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"20734","DOI":"10.1016\/S0021-9258(19)36747-X","article-title":"IMP Dehydrogenase Inhibitors Reduce Intracellular Tetrahydrobiop-terin Levels through Reduction of Intracellular GTP Levels. Indications of the Regulation of GTP Cyclohydrolase I Activity by Restriction of GTP Availability in the Cells","volume":"267","author":"Hatakeyama","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-024-03314-9","article-title":"Effectiveness of Janus Kinase Inhibitors in Relapsing Giant Cell Arteritis in Real-World Clinical Practice and Review of the Literature","volume":"26","author":"Loricera","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_59","first-page":"e91235","article-title":"A Systematic Review of the Use of Janus Kinase Inhibitors in Large Vessel Vasculitis","volume":"17","author":"Chay","year":"2025","journal-title":"Cureus"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ishihara, R., Watanabe, R., Shiomi, M., Fujita, Y., Katsushima, M., Fukumoto, K., Yamada, S., and Hashimoto, M. (2025). The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy. Biomolecules, 15.","DOI":"10.3390\/biom15111586"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive Methotrexate for Treatment of Giant Cell Arteritis: An Individual Patient Data Meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Casta\u00f1eda, S., Prieto-Pe\u00f1a, D., Vicente-Rabaneda, E.F., Triguero-Mart\u00ednez, A., Roy-Vallejo, E., Atienza-Mateo, B., Blanco, R., and Gonz\u00e1lez-Gay, M.A. (2022). Advances in the Treatment of Giant Cell Arteritis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061588"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in Giant Cell Arteritis\/Polymyalgia Rheumatica: A Double-Blind Study","volume":"45","author":"Hazleman","year":"1986","journal-title":"Ann. Rheum. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"120638","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a Corticosteroid-Sparing Agent in Giant Cell Arteritis and Polymyalgia Rheumatica: A Case Series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"rkaa069","DOI":"10.1093\/rap\/rkaa069","article-title":"Evaluation of Adjunctive Mycophenolate for Large Vessel Giant Cell Arteritis","volume":"4","author":"Karabayas","year":"2020","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semarthrit.2012.12.023","article-title":"Is There a Place for Cyclophosphamide in the Treatment of Giant-Cell Arteritis? A Case Series and Systematic Review","volume":"43","author":"Boutemy","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e1004249","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An Open-Label Randomized Controlled Trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/IJGM.S414267","article-title":"Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China","volume":"16","author":"Gu","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/S2665-9913(24)00270-4","article-title":"Baricitinib in Early Polymyalgia Rheumatica (BACHELOR): A Randomised, Double-Blind, Pla-cebo-Controlled, Parallel-Group Trial","volume":"7","author":"Saraux","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Porr\u00faa, C., Heras-Recuero, E., Bl\u00e1zquez-S\u00e1nchez, T., Torres-Rosell\u00f3, A., Casta\u00f1eda, S., and Gonz\u00e1lez-Gay, M.\u00c1. (2024). Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216492"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.13525","article-title":"An Update on Polymyalgia Rheumatica","volume":"292","author":"Lundberg","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_72","first-page":"411","article-title":"Polymyalgia Rheumatica","volume":"119","author":"Colombo","year":"2022","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus Methotrexate for Polymyalgia Rheumatica: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_74","first-page":"624","article-title":"Methotrexate in Polymyalgia Rheumatica: Preliminary Results of an Open, Randomized Study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J. Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can Methotrex-ate Be Used as a Steroid Sparing Agent in the Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis?","volume":"55","author":"Dinant","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","article-title":"Efficacy and Tolerability of Leflunomide in Difficult-to-Treat Polymyalgia Rheumatica and Giant Cell Arteritis: A Case Series: Efficacy and Tolerability of Leflunomide","volume":"66","author":"Adizie","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"rkae033","DOI":"10.1093\/rap\/rkae033","article-title":"Effectiveness of Methotrexate and Leflunomide as Corticoid-Sparing Drugs in Patients with Polymyalgia Rheumatica","volume":"8","author":"Vinicki","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/cts.12618","article-title":"Safety, Pharmacokinetics, and Pharmaco-dynamics of ASP 3662, a Novel 11\u03b2-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects","volume":"12","author":"Bellaire","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ard.2025.10.015","article-title":"Effects of Clofutriben, a Selective 11\u03b2-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, on the Efficacy and Toxicity of Prednisolone in Patients with Polymyalgia Rheumatica: A Single-Blind Controlled Trial with Sequential Cohorts","volume":"85","author":"Buttgereit","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41467-023-36541-w","article-title":"11\u03b2-HSD1 Inhibition in Men Mitigates Prednisolone-Induced Adverse Effects in a Proof-of-Concept Randomised Double-Blind Placebo-Controlled Trial","volume":"14","author":"Othonos","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-019-1972-1","article-title":"11\u03b2-HSD1 Plays a Critical Role in Trabecular Bone Loss Associated with Systemic Glucocorticoid Therapy","volume":"21","author":"Fenton","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e39723","DOI":"10.1097\/MD.0000000000039723","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis: A Bidirectional Mendelian Randomization Study","volume":"103","author":"Teng","year":"2024","journal-title":"Medicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of Polymyalgia Rheumatica 2000\u20132014 and Examination of Incidence and Survival Trends Over 45 Years: A Population-Based Study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-016-1097-8","article-title":"Characteris-ing Those with Incident Polymyalgia Rheumatica in Primary Care: Results from the PMR Cohort Study","volume":"18","author":"Muller","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"103590","DOI":"10.1016\/j.autrev.2024.103590","article-title":"The Pipeline of Immunomodulatory Therapies in Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review of Clinical Trials","volume":"23","author":"Kawka","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/TCRM.S13088","article-title":"Optimal Management of Giant Cell Arteritis and Polymyalgia Rheumatica","volume":"173","author":"Charlton","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11592500-000000000-00000","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis in Older Patients: Diagnosis and Pharmacological Management","volume":"28","author":"Schmidt","year":"2011","journal-title":"Drugs Aging"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Sureda, A., Cor-bacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). Clinically Relevant Drug Interactions in HCT. The EBMT Handbook, Springer International Publishing.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Shawky, A.M., Almalki, F.A., Abdalla, A.N., Abdelazeem, A.H., and Gouda, A.M. (2022). A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051001"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.39333","article-title":"2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism\/American College of Rheumatology Collaborative Initiative","volume":"67","author":"Dejaco","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/rheumatology\/kew264","article-title":"Cost-Effectiveness of Biologic Compared with Conventional Synthetic Disease-Modifying An-ti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Register Study","volume":"55","author":"Joensuu","year":"2016","journal-title":"Rheumatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s10067-025-07360-9","article-title":"Safety of Janus Kinase Inhibitors in Rheumatoid Arthritis: A Disproportionality Analysis Using FAERS Database from 2012 to 2022","volume":"44","author":"Mikaeili","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5414\/CP203901","article-title":"Methotrexate for Treating Polymyalgia Rheumatica: A Meta-Analysis of Randomized Controlled Trials","volume":"59","author":"Song","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"152041","DOI":"10.1016\/j.semarthrit.2022.152041","article-title":"Shared Decision Making in Rheumatology: A Scoping Review","volume":"56","author":"Morrison","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/ggi.12616","article-title":"Systematic Review of the Barriers Affecting Medication Adherence in Older Adults","volume":"16","author":"Yap","year":"2016","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in Elderly People","volume":"381","author":"Clegg","year":"2013","journal-title":"The Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A Global Clinical Measure of Fitness and Frailty in Elderly People","volume":"173","author":"Rockwood","year":"2005","journal-title":"Can. Med. Assoc. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"keaf522","DOI":"10.1093\/rheumatology\/keaf522","article-title":"The 2025 British Society for Rheumatology Guideline for the Prescription and Monitoring of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs","volume":"65","author":"Bechman","year":"2026","journal-title":"Rheumatology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12877-021-02208-8","article-title":"A Systematic Review of the Evidence for Deprescribing Interventions among Older People Living with Frailty","volume":"21","author":"Ibrahim","year":"2021","journal-title":"BMC Geriatr."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:05:31Z","timestamp":1782349531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":100,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["molecules31132218"],"URL":"https:\/\/doi.org\/10.3390\/molecules31132218","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}